Table 2.
Breakdown of patient cohort by individual clinical and pathologic characteristics stratified by ASTRO CS grouping.
| Characteristic |
ASTRO CS grouping No. of patients (%) |
||
|---|---|---|---|
| Suitable N = 58 |
Cautionary N = 119 |
Unsuitable N = 66 |
|
| Age, yrs | |||
| ≥60 | 58 (100) | 89 (75) | 34 (52) |
| 50–59 | 0 (0) | 30 (25) | 4 (6) |
| <50 | 0 (0) | 0 (0) | 28 (42) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
| Tumor Size, cm | |||
| ≤2 | 58 (100) | 63 (53) | 40 (61) |
| 2.1–3.0 | 0 (0) | 9 (8) | 7 (11) |
| >3 | 0 (0) | 0 (0) | 3 (4) |
| DCIS ≤ 3 | 0 (0) | 47 (39) | 14 (21) |
| DCIS > 3 | 0 (0) | 0 (0) | 2 (3) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
| Histology | |||
| IDC | 56 (97) | 60 (51) | 45 (68) |
| ILC | 0 (0) | 9 (8) | 5 (8) |
| DCIS | 0 (0) | 47 (39) | 16 (24) |
| IDC/ILC | 2 (3) | 2 (1) | 0 (0) |
| Adenoid cystic | 0 (0) | 1 (1) | 0 (0) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
| ER status | |||
| Positive | 58 (100) | 87 (73) | 56 (85) |
| Negative | 0 (0) | 31 (26) | 10 (15) |
| Unknowna | 0 (0) | 1 (1) | 0 (0) |
| Margins | |||
| Negative, ≥2 mm | 58 (100) | 72 (61) | 21 (32) |
| Close, <2 mm | 0 (0) | 47 (39) | 17 (26) |
| Positive | 0 (0) | 0 (0) | 28 (42) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
| Multifocality | |||
| None | 58 (100) | 115 (97) | 61 (92) |
| ≤2 cm | 0 (0) | 4 (3) | 3 (5) |
| 2.1 cm–3.0 cm | 0 (0) | 0 (0) | 1 (1.5) |
| >3 cm | 0 (0) | 0 (0) | 1 (1.5) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
| Multicentricity | |||
| Unicentric | 58 (100) | 119 (100) | 66 (100) |
| Multicentric | 0 (0) | 0 (0) | 0 (0) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
| LVI | |||
| None | 54 (93) | 107 (90) | 52 (79) |
| Limited/focal | 0 (0) | 7 (6) | 3 (4.5) |
| Extensive | 0 (0) | 0 (0) | 3 (4.5) |
| Indeterminate | 4 (7) | 5 (4) | 8 (12) |
| Unknown | 0 (0) | 0 (0) | 0 (0) |
| EIC, cmb | |||
| None | 58 (100) | 70 (97) | 47 (94) |
| ≤3 | 0 (0) | 2 (3) | 2 (4) |
| >3 | 0 (0) | 0 (0) | 1 (2) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
| Nodal statusb | |||
| Negative | 58 (100) | 72 (100) | 39 (78) |
| Positive | 0 (0) | 0 (0) | 7 (14) |
| None performed | 0 (0) | 0 (0) | 4 (8) |
| Unknowna | 0 (0) | 0 (0) | 0 (0) |
CS: consensus statement, DCIS: ductal carcinoma in situ, IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, ER: estrogen receptor, LVI: lymphovascular invasion, and EIC: extensive intraductal component.
aPatients with tumor characteristics characterized as unknown or indeterminate were placed in ASTRO categories based on the other criteria.
bExcluding DCIS; cautionary N = 72; unsuitable N = 50.